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AbstrAct
Chemo/radio-therapy resistance to the deadly pancreatic cancer is mainly due to 
the failure to kill pancreatic cancer stem cells (CSCs). Signal transducer and activator 
of transcription 3 (STAT3) is activated in pancreatic CSCs and, therefore, may be a 
valid target for overcoming therapeutic resistance. Here we investigated the potential 
of STAT3 inhibition in sensitizing pancreatic cancer to chemo/radio-therapy. We found 
that the levels of nuclear pSTAT3 in pancreatic cancer correlated with advanced tumor 
grade and poor patient outcome. Liposomal delivery of a STAT3 inhibitor FLLL32 
(Lip-FLLL32) inhibited STAT3 phosphorylation and STAT3 target genes in pancreatic 
cancer cells and tumors. Consequently, Lip-FLLL32 suppressed pancreatic cancer cell 
growth, and exhibited synergetic effects with gemcitabine and radiation treatment 
in vitro and in vivo. Furthermore, Lip-FLLL32 reduced ALDH1-positive CSC population 
and modulated several potential stem cell markers. These results demonstrate that 
Lip-FLLL32 suppresses pancreatic tumor growth and sensitizes pancreatic cancer 
cells to radiotherapy through inhibition of CSCs in a STAT3-dependent manner. By 
targeting pancreatic CSCs, Lip-FLLL32 provides a novel strategy for pancreatic cancer 
therapy via overcoming radioresistance.
INtrODUctION
Pancreatic cancer is estimated to responsible for 
40,560 deaths and 48,960 newly diagnosed cases in the 
United States in 2015 [1]. Most patients die within the first 
year of their diagnosis, setting the five-year survival rate to 
only 6% [2]. Surgery offers the only option to cure patients 
with pancreatic cancer, however, only 20% of patients 
are eligible for surgery [3, 4]. Systemic chemotherapy 
or chemoradiotherapy only has a modest benefit on most 
patients with advanced disease. Both treatments have 
high frequency of relapse and patients develop resistant 
eventually [4, 5]. The failure to kill tumor-initiating cells 
or cancer stem cells (CSCs) by conventional chemo/
radio-therapy is one of the major reasons for recurrence 
and resistance [6, 7]. Targeting molecules and signaling 
pathways associated with CSCs is one of potential 
strategies to overcome these problems.
Recent studies demonstrate that signal transducer 
and activator of transcription 3 (STAT3) plays critical 
roles in initiation and progression of pancreatic cancer, 
especially in mutant KRAS-mediated pancreatic ductal 
adenocarcinomas (PDAC) [8–10]. In response to 
cytokines or growth factors, activated STAT3 functions 
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as a nuclear transcription factor by regulating genes 
involved in proliferation, survival, angiogenesis and 
invasion, as well as genes encoding key cancer-promoting 
inflammatory mediators [11, 12]. More importantly, 
STAT3 signaling has central roles in CSC maintenance 
[11, 13, 14] and therapeutic resistance [15, 16]. We have 
shown that blocking upstream activators of STAT3 inhibits 
pancreatic tumor growth and post-radiation recurrence 
partly by eradicating CSCs [17, 18]. Since STAT3 serves 
as a point of convergence for numerous oncogenic 
signaling pathways, directly targeting STAT3 might be a 
more effective strategy for pancreatic cancer treatment, 
especially for overcoming chemo/radio-therapy resistance 
that derives from CSCs.
Inhibiting intermolecular interactions between STAT3 
and upstream proteins by targeting STAT3 Src homology-2 
(SH2) domain is one of strategies that directly block STAT3 
activity [19]. FLLL32, an analogue of Curcumin, was 
designed to selectively bind to STAT3 SH2 domain, thereby 
inhibiting STAT3 phosphorylation and DNA-binding activity 
[20]. FLLL32 potently and specifically inhibited STAT3 
(no inhibition of STAT1) and exhibited growth-repressive 
activity in cancer cells with constitutively activated STAT3 
[20–22]. However, the delivery of FLLL32 has been limited 
by its low aqueous solubility, which is the same as its parent 
compound. Many in vivo studies introduced intraperitoneal 
injection of FLLL32 dissolved in Dimethyl sulfoxide 
(DMSO) or Cremophor EL/ethanol formulation [20, 23, 24]. 
These are compromising formulations due to the fact that 
high dose of DMSO is toxic and Cremophor is associated 
with serious side effects of hypersensitivity, nephrotoxicity 
and neurotoxicity [25, 26]. Moreover, drug efficacy is 
lower when administrated by intraperitoneal injection 
than by intravenous (i.v.) injection. Thus, in this study, we 
prepared PEGylated liposomal FLLL32 that allowed for i.v. 
administration. In addition to its enhanced biocompatibility 
and reduced toxicity, PEGylated liposomes with size around 
100 nM can be passively delivered into solid tumors via the 
“enhanced permeability and retention (EPR)” effect [27, 28] 
and escape the reticulo-endothelial system (RES) clearance 
with the PEG shielding effect [29]. 
Here, we show for the first time that liposomal delivery 
of FLLL32, a STAT3 phosphorylation inhibitor, efficiently 
suppressed pancreatic cancer xenograft tumor growth, and 
sensitized pancreatic cancer cells to radiotherapy in vitro and 
in vivo by inhibiting STAT3 signaling in CSCs potentially. 
rEsULts 
Increased pstAt3 expression in human 
pancreatic adenocarcinoma is associated with 
poor clinical outcome
To explore the clinic-pathological significance of 
pSTAT3 in pancreatic cancer and the utility of STAT3 
inhibition in sensitizing pancreatic cancer to chemo/
radio-therapy, we first measured pSTAT3 expression by 
immunohistochemistry in 156 pancreatic cancer samples 
paired with normal tissues resected from primary pancreatic 
tumors and adjacent non-tumor areas. Nuclear pSTAT3 was 
negative to weakly expressed (defined as low expression) in 
normal pancreas (88.6%) and chronic pancreatitis (60.3%), 
while was expressed moderately to strongly (defined as 
high expression) in PDAC (50.6%) (Figure 1A and 1B). 
The ratio of high nuclear pSTAT3 expression in PDAC was 
significantly higher than that of in normal pancreas (50.6% 
vs 11.4%).
We next investigated the correlation between nuclear 
pSTAT3 expression and clinic-pathological parameters. 
To begin with, we examined the association of nuclear 
pSTAT3 expression with survival status of 60 pancreatic 
cancer patients that had available survival data by Kaplan-
Meier survival analysis. Patients with high pSTAT3 
expression had a shorter median survival time than patients 
with low pSTAT3 expression (13 months vs. 30 months, 
P = 0.207, log-rank test, Figure 1C), though did not reach 
statistical significance. The 5-year survival rate for patients 
whose tumors expressed either high or low levels of 
pSTAT3 was of 28% and 44%, respectively. However, high 
expression of nuclear pSTAT3 was significantly correlated 
with high tumor grade (P = 0.0259) and glandular cancer 
(P = 0.037) (Figure 1D, Supplementary Table 1). No 
significant correlation exists in age, gender, tumor size and 
location, TNM stage, AJCC stage, smoking, drinking as 
well as patient survival. Taken together, increased nuclear 
pSTAT3 staining correlates with advanced tumor grade 
and poor patient outcome. Therefore, targeting STAT3 
by small molecule inhibitor FLLL32 could be a potential 
therapeutic strategy for inhibiting pancreatic cancer 
progression and overcoming chemo/radio- resistance.
Liposomal FLLL32 is effectively and specifically 
delivered into pancreatic tumors 
To improve in vivo delivery of FLLL32, we prepared 
liposomes encapsulating FLLL32 (Lip-FLLL32) by thin-
film hydration method. Empty liposomes (Lip only) were 
also prepared as a vehicle control. The sizes of Lip only 
and Lip-FLLL32 were 78.92 ± 5.54 nm (n = 3) and 92.29 
± 8.19 nm (n = 3), respectively, measured by dynamic laser 
scattering. This size distribution of Lip-FLLL32 indicates 
that it could passively target solid tumors via increased 
permeable tumor vasculature known as the “enhanced 
permeability and retention (EPR)” effect, as it is generally 
assumed that particles less than 200 nm in diameter are able 
to extravasate to the tumor site [27]. Representative size 
distributions of both were shown in Figure 2A. By scanning 
transmission electron microscopy (STEM), we found 
that the surface of Lip-FLLL32 was bumpy, indicative of 
successful embedding of FLLL32 into the liposome, while 
the surface of Lip only was smooth (Figure 2B). 
Next, we investigated the tumor-targeting efficiency 
and biodistribution of Lip-FLLL32 in the PANC-1 xenograft 
mouse model. We encapsulated FLLL32 into the liposomes 
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together with DiR, a lipophilic NIR fluorescence dye, which 
can be used to track the delivery of the liposomes in vivo. 
The liposomes were administered by tail vein injection into 
nude mice containing PANC-1 xenografts. The fluorescence 
signals were determined 24 h after injection. The xenografts 
in the mice injected with liposomal DiR plus FLLL32 had 
significantly stronger fluorescence signals than that of in the 
mouse injected with free DiR, whose fluorescence signals 
were limited to the tail but not to the tumors (Figure 2C). 
This result indicated that the liposomal FLLL32 was 
specifically delivered to the xenografts. We further 
compared the fluorescence intensity of tumors with that 
of other organs. As shown in Figure 2D, the fluorescence 
intensity ratios of tumor to heart or lung in the mice injected 
with liposomal DiR plus FLLL32 were 3.1 or 7.1 folds 
of that in mouse injected with free DiR (19.2 ± 2.6 vs. 
6.1 ± 2 .3, P < 0.001 for heart, and 5.0 ± 0.3 vs. 0.7 ± 0.3, 
P < 0.01 for lung, respectively.). As for liver and spleen, the 
two main internal organs that are involved in nonspecific 
clearance of nanoparticles through their reticuloendothelial 
system (RES), the tumor/liver or tumor/spleen ratios in 
liposomal DiR and FLLL32 treated mice were 1.5 ± 0.2 
or 1.6 ± 0.01, which were 2.9 or 3.8 folds of that in the 
mouse injected with free DiR, respectively. In addition, 
the fluorescent intensity of tumors given liposomal DiR 
and FLLL32 was about 4-fold higher than that of tumors 
received free DiR (Figure S1). All these data reveal that 
Lip-FLLL32 was effectively and specifically accumulated 
in tumors after systemic administration in vivo.
Lip-FLLL32 dose-dependently inhibits stAt3 
phosphorylation and transcriptional activity
To validate whether Lip-FLLL32 effectively inhibits 
STAT3 phosphorylation and its transcriptional activity as 
FLLL-32 does, we firstly screened the optimal inhibitory 
concentration of FLLL32 for PANC-1 and BxPC-3 cells, 
which have constitutively activated STAT3. As shown in 
Figure S2A, FLLL32 dose-dependently down-regulated the 
protein levels of pSTAT3 and its target Cyclin D1, Survivin 
Figure 1: Increased nuclear pstAt3 expression in human pancreatic adenocarcinoma is associated with poor clinical 
outcome. (A) Representative images of pSTAT3 immunohistochemistry staining in pancreatic tissues (Bar: 100.8 μm. Magnification: 
400×). Black arrows highlight positive staining. (b) Percentage of nuclear pSTAT3 expression in non-neoplastic tissue and PDCA. *The 
percentage of high nuclear pSTAT3 in chronic pancreatitis and pancreatic cancer was compared to that of normal pancreas. aThe percentage 
of high nuclear pSTAT3 in pancreatic cancer was compared to that of chronic pancreatitis. Chi-square test. (c) Kaplan-Meier analysis of 
the overall survival of 60 patients comparing high and low nuclear pSTAT3. Patients with high pSTAT3 have a shorter medium survival 
comparing to those with low pSTAT3 (13 months vs 30 months, P = 0.207, log-rank test). (D) Nuclear pSTAT3 expression in pancreatic 
tissues with low grade or high grade. Patients with high grade tumors (ΙΙΙ, n = 37) have higher nuclear pSTAT3 expression compared to 
those with low grade tumors (Ι + ΙΙ, n = 119) (p = 0.0259, t-test).
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and Bcl-xL, whereas increased cleaved PARP, with totally 
blockage of pSTAT3 at the concentration of 5 µM for PANC-
1 and 1 µM for BxPC-3, respectively. We then determined 
the effect of Lip-FLLL32 on STAT3 phosphorylation and its 
corresponding target genes expression by 5 µM at different 
time points for PANC-1. Similar to FLLL32, Lip-FLLL32 
reduced the protein level of pSTAT3, Bcl-xL and Survivin 
in a time-dependent manner (Figure 3A). However, the time 
point of totally blockage of pSTAT3 and its target proteins 
in Lip-FLLL32 treated cells occurred 12 h later than in 
free FLLL32 treated cells, which might be due to the slow 
release of FLLL32 from the liposomes. Furthermore, we 
Figure 2: Lip-FLLL32 is effectively delivered to pancreatic tumors. (A) Representative size distributions of empty liposome 
(up) and Lip-FLLL32 (down) measured by Malvern Nano-ZS90. (b) Representative STEM images of empty liposome (up) and Lip-
FLLL32 (down). Black arrows highlight the typical liposomes. Biodistribution study: (c) NIR and X-ray overlaid image of mice 24 hours 
after injection of free DiR or liposomal DiR and FLLL32. White arrows highlight the tumors. Intensity bar is shown at the bottom. (D) The 
tumor/non-tumor ratios of fluorescence intensity in mice 96 hours after injection of free DiR or liposomal DiR and FLLL32 (*P < 0.05, 
**P < 0.01, ***P < 0.001, two-way ANOVA, n = 2).
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measured pSTAT3 transcriptional activity using luciferase 
assay as described previously [20]. We found both FLLL32 
and Lip-FLLL32 dose-dependently decreased pSTAT3 
transcriptional activity, although Lip-FLLL32 required a 
two-fold higher dose than that of FLLL32 to achieve the 
same inhibitory effect, which might be also due to the slower 
release feature of Lip-FLLL32 (Figure 3B). Therefore, these 
data indicate that Lip-FLLL32 is functionally effective in 
inhibiting pSTAT3 signaling, although it required relatively 
longer time as compared to free FLLL32. Nevertheless, 
the delayed inhibition of pSTAT3 pathway may provide an 
advantage of Lip-FLLL32 in long-term administration. 
Lip-FLLL32 effectively inhibits pancreatic 
cancer cell growth in vitro and in vivo 
To further determine whether Lip-FLLL32 inhibits 
cell growth in vitro as FLLL32 does, we carried out the 
MTT-based cytotoxicity assay of Lip-FLLL32 against 
a panel of pancreatic cancer cell lines as well as an 
immortalized human lung fibroblast cell line WI-38. 
We found that both FLLL32 and Lip-FLLL32 dose-
dependently inhibited cell growth in all the pancreatic 
cancer cell lines tested, but not in WI-38 cells which have 
low level of pSTAT3 (Figure 3C & Figure S2B). The IC50 
values of Lip-FLLL32 for all detected cell lines were 
approximately two-fold as that of FLLL32, consistent 
with their inhibitory effects on STAT3 phosphorylation 
and transcriptional activity. But in colony formation assays 
which were carried out as described previously [30, 31], 
both FLLL32 and Lip-FLLL32 dose-dependently decreased 
the plating efficiency in PANC-1 and BxPC-3 cells at the 
equal dose and the equal time (Figure 3D). Different from 
the cytotoxicity assay and Western blot based pSTAT3 
detection that treatment lasted less than 96 hours, colony 
formation assay required longer time (usually up to two 
weeks) of treatment, in which time frame encapsulated 
FLLL32 might be completely released from the liposomes. 
Thus, the same extent of inhibitory effects by Lip-FLLL32 
and FLLL32 were detected.
Next, we examined whether Lip-FLLL32 had safely 
therapeutic effects in vivo, which require efficient drug 
delivery during long-term administration. To begin with, 
we first determined the maximal tolerated dose (MTD) 
of Lip-FLLL32 in mice, with Cremophor formulated 
FLLL32 (C-FLLL32) as a solvent control. As shown in 
Supplementary Table 2, the MTD for liposomal FLLL32 
is over 22.5 mg/kg but for C-FLLL32 is only 15 mg/kg, 
indicating liposomal FLLL32 is more tolerable in mice. 
Based on this data, 15 mg/kg Lip-FLLL32 or C-FLLL32 
was chosen for in vivo efficacy studies. When administrated 
alone, both Lip-FLLL32 and C-FLLL32 significantly 
inhibited tumor growth (P < 0.001 versus untreated 
control group for both formulations, n = 10, Figure 4A), 
and prolonged the tumor-doubling time correspondingly 
(P < 0.01 versus untreated group for both formulations, 
n = 10, Figure 4B). There was no statistical difference 
between C-FLLL32 and Lip-FLLL32 in reducing tumor 
growth. The median tumor doubling time was 15, 25, and 
29 days for the control group, C-FLLL32 group and Lip-
FLLL32 group respectively, indicating that Lip-FLLL32 
more efficiently delayed tumor growth than C-FLLL32 
at the same dosage although there was no significant 
difference between the two in the tumor-doubling time 
curves. During the experimental period, the bodyweight of 
the control mice and two FLLL32-treated mice all changed 
within 10%, thus both C-FLLL32 and Lip-FLLL32 at the 
dose of 15 mg/kg of FLLL32 were well tolerated in mice 
(Figure S3A).
To determine whether the in vivo tumor growth 
inhibitory effect of Lip-FLLL32 was connected to the 
reduction of STAT3 phosphorylation and transcriptional 
activity, one tumor from each group after one-week’s 
treatment was removed to detect the expression of 
pSTAT3 and its target genes. We found that the pSTAT3 
protein levels in both C-FLLL32 and Lip-FLLL32 
treated tumors were greatly down-regulated (Figure 4C). 
Meanwhile, qRT-PCR analysis revealed that the relative 
mRNA levels of STAT3 target genes Bcl-xL, Survivin and 
CCND1 were all sharply decreased by 80% in two treated 
tumors, as compared to the untreated control (P < 0.001 
for both treatments, Figure 4D). These results suggested 
that FLLL32 at the dose of 15 mg/kg delivered by the 
two formulations inhibited STAT3 phosphorylation and 
transcriptional activity at the similar extent in vivo. To 
investigate how Lip-FLLL32 decreased tumor growth, 
tumor tissues at the end of treatment were collected 
and processed for histologic examination of apoptosis 
using TUNEL staining and angiogenesis using CD31 
immunostaining. Both C-FLLL32 and Lip-FLLL32 
treatment significantly increased TUNEL-positive tumor 
cells and reduced CD31-postitive endothelial cells 
than untreated control (Figure S3B–S3C). This result 
demonstrates that Lip-FLLL32 inhibited tumor growth 
via inducing tumor cell apoptosis and reducing tumor 
angiogenesis. This is consistent with the fact that STAT3 
downstream targets are involved in anti-apoptotic and 
angiogenesis pathways. Taken together, Lip-FLLL32 
efficiently and safely delayed in vivo pancreatic tumor 
growth in a STAT3-dependent manner.
Lip-FLLL32 sensitized pancreatic cancer to 
chemo/radio-therapy
In pancreatic cancer, neither chemotherapy nor 
radiotherapy alone is able to effectively block cancer 
progression and both treatments develop resistance 
eventually [4, 32]. Besides, indirect inhibition of STAT3 
phosphorylation/activation alone using small molecules 
that antagonize STAT3 upstream growth factor and 
cytokine receptor only shows modest efficacy [19]. We 
thus turned to explore whether directly targeting STAT3 
with Lip-FLLL32 could enhance the inhibitory efficacy 
of gemcitabine or radiation on pancreatic cancer tumor 
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growth. We first examined the sensitivity alteration of 
PANC-1 cells to gemcitabine with or without combined 
STAT3 inhibition. As shown in Figure 5A, with the doses 
of free FLLL32 or Lip-FLLL32 increased, the IC50 of 
gemcitabine decreased correspondingly, suggesting that 
both free FLLL32 and Lip-FLLL32 sensitized PANC-1 
cells to gemcitabine (Figure 5A). In comparison to free 
FLLL32, Lip-FLLL32 exhibited similar inhibition at the 
higher dose, potentially due to its slow release during this 
short time period of 96 hours. However, in the clonogenic 
assays which were carried out as described previously 
[31] and lasted for two weeks, both free FLLL32 and Lip-
FLLL32 enhanced radiation-induced clonogenic cell death 
in the same degree with a radiation dose enhancement 
ratio (ER) of 1.73 and 1.64, respectively (Figure 5B). 
Since the ER values are larger than 1.20 [33], both free 
FLLL32 and Lip-FLLL32 are considered to be able to 
radiosensitize pancreatic cancer. These in vitro results 
Figure 3: Lip-FLLL32 inhibits pancreatic cancer cell growth in vitro in a stAt3 dependent way. (A) Western blot analysis 
of total STAT3, pSTAT3 and its target proteins in PANC-1 cells treated with 5 µM FLLL32 or Lip-FLLL32 at indicated time points. 
β-Actin was used as loading control. (b) STAT3-dependent transcriptional luciferase activity assay in PANC-1 cells treated with FLLL32 
or Lip-FLLL32. PANC-1 cells were co-transfected with pLucTKS3 luciferase reporter construct and beta-galactosidase plasmid, and then 
treated with FLLL32 or Lip-FLLL32 for 24 hours. Values are mean ± SD from two independent experiments. *P < 0.05, **P < 0.01, 
***P < 0.001, one-way ANOVA. (c) The cytotoxicity of free FLLL32 (left) and Lip-FLLL32 (right) against BxPC-3, PANC-1 and WI-
38 cell lines. (D) Colony formation assay in PANC-1 (left) and BxPC-3 (right) cells treated with free FLLL32 or lip-FLLL32 at indicated 
doses. DMSO was used as vehicle control of FLLL32 and Lip only was used as vehicle control of Lip-FLLL32. *P < 0.05, **P < 0.01, 
***P < 0.001, two-way ANOVA. 
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demonstrate that liposomal FLLL32 potentially sensitize 
patients to chemotherapy or radiotherapy.
We next examined the radiosensitization potential of 
Lip-FLLL32 in vivo in PANC-1 xenograft mouse model. 
As shown in Figure 5C, X-ray radiation or Lip-FLLL32 
alone significantly inhibited tumor growth (P < 0.001 versus 
control group for both groups, n = 9). But when radiation 
was combined with Lip-FLLL32, tumors were shrunk 
significantly as compared to radiation alone (P < 0.001). 
Doubling time of tumors in each group was shown in 
Figure 5D. Either radiation or liposomal FLLL32 treatment 
alone delayed tumor doubling time by 7 days as compared 
to Lip only control group (P < 0.01, n = 9), whereas the 
combination of liposomal FLLL32 with radiation delayed 
Figure 4: Lip-FLLL32 inhibits pancreatic cancer xenograft growth in vivo in a stAt3 dependent way. Nude mice bearing 
PANC-1 xenografts were intravenously injected with 15 mg/kg Cremophor formulated FLLL32 or 15 mg/kg liposome formulated FLLL32 
three times a week for three weeks or left untreated. (A) Tumor growth curves of mice in three groups were plotted up to Day 46. The data are 
mean ± SEM (n = 10). ***P < 0.001, two-way ANOVA, by comparing C-FLLL32 or Lip-FLLL32 treated group with untreated control group 
at day 36. (b) Kaplan-Meier analysis of tumor size doubling time of mice in three groups. The medium doubling time for control, C-FLL32 
and Lip-FLLL32 is 15, 25 and 29, respectively. **P < 0.01, log-rank test, by comparing two treated groups with untreated control group. 
(c) Phosphorylation and total STAT3 protein expression levels were analyzed in representative tumor samples from untreated control, 
C-FLLL32 and Lip-FLLL32 treated groups. (D) qRT-PCR analysis of relative mRNA levels of STAT3 target genes in xenograft tumor 
samples. ***P < 0.001, two-way ANOVA, by comparing C-FLLL32 or Lip-FLLL32 treated sample with untreated control sample.
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Figure 5: Lip-FLLL32 sensitizes pancreatic cancer to chemo/radiotherapy. (A) Cytotoxicity of Gemcitabine combination 
with free FLLL32 (left) or Lip-FLLL32 (right) against PANC-1 cells. (b) Clonogenic survival assay of PANC-1 cells treated by FLLL32, 
radiotherapy or their combination. Survival fractions were plotted, and the enhancement ratios (ER) by FLLL32 or Lip-FLLL32 were 
calculated vs. DMSO. (c) PANC-1 xenograft nude mice were treated with empty liposome, 2 Gy radiation, 15 mg/kg Lip-FLLL32 or 
combination three times a week for three weeks. Tumor growth curves of mice were plotted up to Day 43. The data are mean ± SEM 
(n = 9). ***P < 0.001, two-way ANOVA, by comparing Radiation, Lip-FLLL32 or combination treated group with Lip only group at day 
25; a, P < 0.001, two-way ANOVA, by comparing combination group with Radiation group. (D) Kaplan-Meier analysis of tumor size 
doubling time of mice in four groups. The medium doubling time for Lip only, Radiation, Lip-FLLL32 and combination treated groups 
is 15, 22, 22 and 43, respectively. **P < 0.01, ***P < 0.001, log-rank test, by comparing three other groups with untreated control group.
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tumor doubling time for 28 days (P < 0.001, n = 9). The 
bodyweight of the mice in four groups all changed within 
10% (Data not shown). Together, our in vitro and in vivo 
data demonstrate that Lip-FLLL32 sensitizes PANC-1 
xenografts to radiotherapy.
Lip-FLLL32 sensitized pancreatic cancer to 
chemo/radio-therapy by reducing cancer stem 
cells 
Emerging evidence suggests that the persistence of 
CSCs might be the cause of the high frequency of relapse 
and failure of current cancer therapies [34–36]. Since STAT3 
signaling has central roles in CSCs [37–39], our above 
effective combination treatment might be resulted from both 
eliminating the proliferating cancer cells by radiation and 
eradicating CSCs by Lip-FLLL32. To test this hypothesis, 
we investigated whether the Lip-FLLL32 mediated 
suppression of pancreatic cancer cell growth is associated 
with reduction of CSCs and inhibition of their function. 
We first examined the influence of Lip-FLLL32 alone on 
in vitro tumorigenic capability of CSCs by tumorsphere 
culture. As shown in Figure 6A, both free FLLL32 and 
Lip-FLLL32 dose-dependently decreased sphere numbers, 
indicating that FLLL32 can reduce the tumorsphere-forming 
cell population in BxPC-3 cells with the doses tested in this 
assay. Aldehyde dehydrogenase 1 (ALDH1) is a widely 
accepted marker for identifying CSCs [40, 41], especially 
for marking pancreatic cancer cells that have stem cell and 
mesenchymal features [42]. We then determined the effect of 
FLLL32 combined with or without radiotherapy on ALDH1 
positive cells using ALDEFLUOR assay. PANC-1 cells 
were treated with FLLL32 with or without 10 Gy radiation 
and harvested 24 hours later for the assay. 10 µM FLLL32 
reduced the ALDH1+ cell population in PANC-1 cells 
(P < 0.05), and abrogated the radiation-induced increase of 
ALDH1+ cell population (P < 0.01) (Figure 6B). Attenuation 
of radiation-induced ALDH1+ cell population increase 
was also observed at a lower concentration of 5 µM. We 
also examined the ALDH1+ cell population in PANC-1 
xenografts received the combination therapy (Figure 6C 
and S4). Compared to empty liposomes, Lip-FLLL32 
alone significantly inhibited ALDH1+ cell population in 
pancreatic cancer cells (P = 0.0148). Lip-FLLL32 abolished 
the radiation-induced increase of ALDH1+ population to a 
level lower than that of Lip-only control (P = 0.0237). The 
data validate that the above effective combination treatment 
actually eliminated both CSCs and proliferating cancer cells. 
We further screened the Human Stem Cell Primer Library 
to explore other potential stem cell genes that would be 
affected by Lip-FLLL32 (Figure 6D). 17 of the 88 stem 
cell genes screened (19%) had altered expression (> 2-fold) 
after Lip-FLLL32 treatment, including 6 embryonic stem 
cell markers (ITGB1, IFITM2, KIT, LCK, FOXD3 and 
PODXL), 2 ectoderm markers (VIM and NES), 1 trophoblast 
marker (PSG3), and HBB, SCGB3A2, NPPA, SERPINA1, 
GCM1, GAL, PTEN, and ROXO1. Our data suggest that 
Lip-FLLL32 treatment eliminates pancreatic CSCs by 
modulating the expression of a wide spectrum of stem cell 
genes as well as STAT3. 
DIscUssION
In the current study, we found that high nuclear 
pSTAT3 expression correlates with advanced tumor grade 
of pancreatic cancer and poor patient survival. To effectively 
target pSTAT3, we prepared Lip-FLLL32, a liposome-
formulated pSTAT3 inhibitor FLLL32, which efficiently 
suppressed cell growth and colony formation in pancreatic 
cancer cells with constitutively activated STAT3 in vitro and 
inhibited xenograft tumor growth in vivo, accompanied by 
reduction of pSTAT3 and its target genes expression. Lip-
FLLL32 sensitized pancreatic cancer cells to gemcitabine 
chemotherapy and X-ray radiotherapy by repressing 
tumorsphere formulation and reducing ALDH1+ cell 
population in xenograft tumors, suggesting the reduction 
of CSCs. Our results support that Lip-FLLL32 could be a 
promising therapeutic agent sensitizing pancreatic cancer 
cells to chemo/radio-therapy via efficient delivery of 
FLLL32 and then inhibition of STAT3 in vivo.
X-ray radiation is a conventional adjuvant therapy for 
many types of cancer including pancreatic cancer. However, 
resistance and recurrence frequently occur in patients 
receiving radiation therapy. The main mechanism for failure 
of radiation therapy is that radiation only kills the actively 
proliferating differentiated cells but not the resistant CSCs, 
which are reported to be responsible for tumor recurrence 
[43]. In this study, we show that liposomal FLLL32 not only 
inhibits pancreatic cancer cell growth but also sensitizes 
pancreatic cancer cells to radiation by attenuating the 
radiation-induced increase of ALDH1-positive stem cell-
like population. Therefore, combination of radiation with 
liposomal FLLL32 can kill both proliferating cancer cells 
and CSCs through inhibiting pSTAT3, which will lead to 
sensitize pancreatic cancer to radiotherapy and overcome 
CSC-induced recurrence after radiotherapy (Figure 7). 
Strategies for therapeutic intervention into STAT3 
signaling include inhibition of STAT3 activation through 
upstream targets (EGFR, JAK, etc), inhibition of 
intermolecular interaction targeting STAT3 SH2 domain, 
inhibition of nuclear translocation of STAT3, and inhibition 
of STAT3 transcriptional activities [19]. As STAT3 sits at 
a convergence of multiple signaling pathways, upstream 
targets inhibition to block STAT3 activation just has 
moderate efficacy and is easy to gain resistance due to 
activation of alternative pathways commonly happened 
to STAT3 upstream target inhibitors. FLLL32 works as a 
potent small molecule inhibitor of pSTAT3, which binds to 
the SH2 domain of STAT3, and specifically inhibits STAT3 
phosphorylation [20]. 
In this study, we made liposomal formulation of 
FLLL32 to improve its aqueous solubility for in vivo 
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delivery. Liposomes are versatile drug delivery carriers. 
Delivery of hydrophobic drugs in liposome system not only 
solves aqueous solubility problem and allows those drugs 
to be administrated via i.v. injection, but also passively 
targets them to solid tumors leading to enhanced antitumor 
efficacy. We show that liposome-formulated FLLL32 is 
more concentrated in tumors compared to other organs 
including liver and spleen, two main organs involving in 
nonspecific clearance of nanoparticles. Liposomal FLLL32 
is also more accumulated in tumors comparing to free 
Figure 6: Lip-FLLL32 sensitizes pancreatic cancer to radiotherapy by reducing pancreatic cscs. (A) Tumorsphere 
formation assay of free FLLL32 (left) or liposomal FLLL32 (right) treated PANC-1cells at indicated doses. Spheres of each treatment 
were counted and compared to vehicle controls. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA. (b) Flow cytometry analysis 
of ALDH1+ population in PANC-1 cells treated with FLLL32 at indicated doses for 24 hours combining with or without 10 Gy radiation 
treatment. *P < 0.05, **P < 0.01, two-way ANOVA; a, P < 0.01, t-test, Radiation only vs no treatment. (c) Flow cytometry analysis of 
ALDH1+ population in xenograft tumor samples from mice treated with Lip only, radiation, liposomal FLLL32, or their combination for 
one week. (D) The relative mRNA expression of stem cell-associated genes in Lip-FLLL32 treated PANC-1 cells was analyzed using 
Human Stem Cell Primer Library and quantitative real-time reverse transcription PCR. Gene expression in Lip-FLLL32 treated cells was 
normalized to β-actin and β-2-microglobulin and set relative to that of Lip only treated PANC-1 cells.
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FLLL32. Thus Lip-FLLL32 prepared here with PEG-
coating and well-controlled size can efficiently deliver 
FLLL32 and accumulated in tumors in vivo.
Liposomal FLLL32 is about two-fold less efficient 
than free FLLL32 in short-term in vitro assays (cytotoxicity 
and reporter assays). This may be due to the slow release 
property of liposomes, since it takes 12 hours more to 
inhibit pSTAT3 and downstream genes at same amount for 
encapsulated FLLL32 than that of free FLLL32. As a matter 
of fact, liposomal FLLL32 and free FLLL32 show similar 
effects in long-term in vitro assays (colony, tumorsphere 
formation and clonogenic assays). The maximal tolerated 
dose (MTD) of FLLL32 in liposomal formulation is 
higher than that of FLLL32 in Cremophor formulation, 
demonstrating that liposomal FLLL32 is safer and less 
toxic in vivo. The MTD of Cremophor formulation is used 
in the in vivo efficacy study to compare two formulations 
directly. Although liposomal FLLL32 does not display 
obvious advantage in inhibiting tumor growth at the same 
dosage compared to FLLL32 in Cremophor formulation, it 
more efficiently delays tumor growth. Furthermore, higher 
MTD and better tumor/non-tumor ratios make it possible to 
achieve better anti-tumor efficacy at a higher dose. 
Tumor-associated inflammation has been recognized 
as an important hallmark of cancer including pancreatic 
cancer [44]. It promotes tumor development and progression. 
Recent evidence suggests that STAT3 plays a crucial role in 
inducing and maintaining a pro-carcinogenic inflammatory 
Figure 7: Proposed working model. (A) Schematic representation of PEGylated liposomes encapsulating FLLL32 as spherical 
vesicles. FLLL32 (silver balls) and cholesterol (green balls) are encapsulated inside of the lipid bilayer formed by EPC (blue hydrophilic 
heads and deep yellow hydrophobic tails) with PEG coating (cyan sticks). (b) Schematic representation of FLLL32 delivery, intracellular 
releasing and affecting processes. Upon release from liposome in the cytosol, FLLL32 binds to the SH2 domain of STAT3, which inhibits 
the phosphorylation, dimerization and nuclear transloacation of STAT3 and subsequently transcription of STAT3 target genes. (c) Working 
model of combination therapy. Radiotherapy only eliminates proliferating cancer cells, while combination treatment results in both killing 
of proliferating cancer cells and eradicating of CSCs by Lip-FLLL32.
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microenvironment [11]. It is found that STAT3 forms a 
positive loop with two inflammatory cytokines IL-6 and 
IL-11 in pancreatic cancer: STAT3 directly affects the 
expression of IL-6 and IL-11, both of which are STAT3 
activating cytokines [9, 45, 46]. So it would be attractive 
to investigate if Lip-FLLL32 treatment inhibits pancreatic 
cancer growth, at least in part, through interfering tumor 
microenvironment. 
Lastly, we identify that Lip-FLLL32 treatment in 
PANC-1 cells affects expression of 17 more stem cell 
genes by PCR array. We will further explore Lip-FLLL32’s 
function in CSCs. The detailed mechanisms of Lip-FLLL32 
modulating those genes, dependent or independent of 
STAT3 inhibition, selectively in cancer or not, are still 
under investigation.
In conclusion, we describe the delivery of a STAT3 
inhibitor, FLLL32, by liposomes (Figure 7A), which 
improves not only the bioavailability of FLLL32 but 
also the selective distribution of FLLL32 to pancreatic 
tumors. By targeting STAT3, Lip-FLLL32 inhibits both 
proliferating pancreatic cancer cells and pancreatic cancer 
stem cells, resulting in reversal of radioresistance induced 
by CSCs (Figure 7B–7C). Therefore, our data provide 
basis for a promising therapeutic strategy for the deadly 
pancreatic cancer.
MAtErIALs AND MEtHODs 
cell culture and reagents
Human pancreatic cancer cell lines and normal 
human lung fibroblast cell line WI-38 were purchased from 
American Type Culture Collection and cultured in high-
glucose Dulbecco’s modified Eagle medium (DMEM; 
HyClone) supplemented with 10% fetal bovine serum 
(FBS; HyClone) and 1% antibiotics (HyClone) in a 5% 
CO2 humidified incubator at 37°C. The reagents cholesterol, 
L-α-phosphatidylcholine (Egg PC) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine- N-[methoxy (polyethylene 
glycol)-2000] (ammonium salt; DSPE-PEG-OMe) were 
purchased from Avanti Polar Lipids. 1,1′-Dioctadecyl-
3,3,3′,3′-Tetramethylindotricarbocyanine Iodide (DiR; 
DiIC18(7)) was purchased from Life Technologies. FLLL32 
and pLucTK, pLucTKS3 luciferase reporter constructs were 
prepared as described previously [20]. Antibodies against 
STAT3, Phospho-STAT3 (Tyr705), PARP, and Bcl-xL were 
purchased from Cell Signaling Technology, Cyclin D1 
(H-295) and Bcl-2 (C-2) were purchased from Santa Cruz 
Biotechnology. Anti-Survivin antibody was obtained from 
Novus Biologicals and anti-β-Actin (AC–74) was obtained 
from Sigma. Primers with the following sequences for qRT-
PCR were obtained from Integrated DNA technologies: 
Bcl-xL forward 5′-ATG GGG TAA ACT GGG GTC G-3′ 
and reverse 5′-GGC TCT AGG TGG TCA TTC AGG-3′, 
CCND1 forward 5′-CCG TCC ATG CGG AAG ATC-3′ 
and reverse 5′-ATG GCC AGC GGG AAG AC-3′, Survivin 
forward 5′-TGC CTG GCA GCC CTT TC-3′ and reverse 5′-
CCT CCA AGA AGG GCC AGT TC-3′, 18srRNA forward 
5′-GTA ACC CGT TGA ACC CCA TT-3′ and reverse 5′-
CCA TCC AAT CGG TAG TAG CG-3′.
tissue samples
Tissues samples of 156 pairs of pancreatic cancer 
tissue and adjacent non-tumor tissues (within the cancer edge 
of 5 cm) were obtained from National Engineering Center for 
Biochip (NECB) in China. The following histopathological 
factors were evaluated: tumor histologic subtype, grade, 
tumor size, location, TNM stage, and pathological stage 
according to the 2009 American Joint Committee on Cancer 
(AJCC) TNM staging system (7th edition). Follow-up 
data was included: date of pancreatectomy, survival status, 
date of death, and/or date of last follow-up. This study was 
reviewed and approved by the Institutional Review Board of 
the Fourth Military Medical University, Xi’an, China.
Immunohistochemistry analysis
TMA staining was performed by standard 
immunohistochemistry procedures [47]. To confirm 
the specificity of the primary antibodies, tissue sections 
were incubated in the absence of the primary antibodies 
and with control mouse IgG. The number of positively 
stained cells and the intensity of positive staining were 
independently scored by 2 pathologists in a blinded manner. 
The percentage of positive stained cells was scored as: 0, no 
colored cells; 1, 1–9%; 2, 10–49%; 3, 50–79%; 4, 80–100%. 
The intensity of positive immunostaining was classified 
into four categories: 0, 1, 2, and 3 representing no visible 
staining; light brown, mid-brown and dark brown staining, 
respectively, with the same intensity covering more than 
75% of the staining area. The immunostaining of each tissue 
was assessed in 5 areas of the acquired images of each tissue 
section and the mean of these 5 scores was calculated. The 
total immunostaining score was calculated by multiplying 
intensity score by positivity score, and categorized as four 
expression subgroups: no, negative total score; weak, total 
score 1–4; moderate, total score 5–8; intense, total score 
9–12. For statistical analysis, the stained tumor tissues were 
divided into two groups: the low-expression group (score 
≤ 4, no to weak) and the high-expression group (score > 4, 
moderate to intense).
Preparation of Liposome-encapsulated FLLL32 
(Lip-FLLL32)
Liposomal FLLL32 was prepared by dissolving co-
lipids (cholesterol, Egg PC and DSPE-PEG-OMe) and 
FLLL32 in chloroform at a 2:18:1:2 ratio in a glass vial. The 
organic solvent was removed by vacuum and the remaining 
dried film was then kept under high vacuum overnight. PBS 
(in vitro) or 5% dextrose (in vivo) was added to the vacuum-
dried lipid film and the mixture was allowed to hydrate 
for 30 min by shaken in a 45°C water bath to generate 
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multilamellar vesicles. Small unilamellar vesicles were 
then prepared by sonication of the multilamellar vesicles 
in an ice bath for 20–30 min until clarity, using a probe 
sonicator at 50% duty cycle. Empty liposome (Lip only) 
was prepared using the same procedure without FLLL32, 
while liposomal DiR was prepared by dissolving co-lipids 
(cholesterol, Egg PC and DSPE-PEG-OMe), FLLL32 and 
DiR in chloroform at a 2:18:1:2:0.2 ratio. The particle size 
and zeta potential of prepared liposome were determined by 
Malvern Zetasizer Nano-zs90. 
scanning transmission electron microscopy 
(stEM)
6 μL of Lip only or Lip-FLLL32 (1:1 dilution by nano 
water) was dropped to the grid and wicked off immediately 
(kim wipe). The grid was let dry for 3 min following by 
adding 10 μL 4% of uranyl acetate (UA) in DI water and 
incubating for 5 min. UA was then wicked off and the grid 
was let dry for another 1 min and put in grid holder until 
ready to view under FEI Tecnai G2 Polara 200 kV TEM.
tumorsphere culture
FLLL32 or Lip-FLLL32 treated cells were suspended 
in DMEM/F12 serum-free medium containing 1% N2, 2% 
B27, 1% antibotic-antimycotic (Invitrogen), 20 ng/ml human 
FGF-2 (Sigma), and 100 ng/ml EGF (Invitrogen), and were 
plated in 24-well ultra-low attachment plates (Corning) with 
2,000 cells per well. Ten to14 days later, spheres in plates 
were quantified using an inverted microscope (Olympus) at 
100×, 200×, and 400× magnifications.
Animal model: in vivo analysis of MtD, 
biodistribution and therapeutic efficacy
Female athymicNCr-nu/nu mice of 5–6 weeks old 
were used for maximal tolerated dose (MTD) study. Three 
mice in each group were administrated with gradually 
increased doses of FLLL32 (10 mg/kg, 15 mg/kg and 
22.5 mg/kg) in liposome or Cremophor formulation via tail 
i.v. injection every other day. Mice status and body weight 
were monitored every day. The dose that causes mice 
with body weight decreased more than 20% is considered 
intolerable. For the following experiments, each mice was 
inoculated subcutaneously on both flanks with 5 × 106 cells 
in 0.2 mL DMEM. Tumor sizes were measured using a 
caliper twice a week. Tumor volume was calculated using 
the formula: (length × width2)/2, as we described previously 
[48]. In biodistribution study, three mice with tumor size 
around 200 mm3 were used: one mouse was administrated 
with 200 μL DiR in 10% ethanol through tail i.v. injection, 
the other two were administrated with 200 μL liposomal 
DiR and FLLL32, and the concentration of DiR in both 
formulations was 0.1 mg/ml. At scheduled time points, 
mice were anesthetized and scanned using a Carestream 
Molecular Imaging System, in vivo Multispectral FX PRO, 
with the excitation at 750 nm and the emission at 830 nm 
using a 30s exposure time. X-ray images were also taken 
for tumor location and over laid with corresponding near-
infrared (NIR) images. 96 h after injection, the mice were 
euthanized by CO2 overdose, main organs and tumors were 
isolated and taken NIR and X-ray imaging. In efficacy study, 
the mice with tumors around 100 mm3 were randomized to 
3 or 4 groups with 6 mice each group. In monotherapy study, 
mice were administrated with 15 mg/kg FLLL32 or Lip-
FLLL32 by tail i.v. injection three times per week for three 
weeks, or left untreated as a control group. Free FLLL32 
was formulated in a vehicle composed of a 1:1 blend of 
Cremophor®EL (polyethoxylated castor oil) and ethanol, 
which was diluted 5-fold by 5% dextrose solution before 
administration. In combination therapy, mice were received 
with Lip only, 2 Gy X-ray radiation, 15 mg/kg Lip-FLLL32 
or 2 Gy X-ray radiation plus 15 mg/kg Lip-FLLL32 three 
times per week for three weeks, respectively. The tumor sizes 
and animal body weights were measured twice a week. After 
one-week treatment, one mouse from each group was sacrificed 
and tumors were dissected for western blot, PCR or ALDH1 
staining. At the end of treatment, one tumor from each group 
was collected for histologic analysis including hematoxylin and 
eosin (H & E) staining, terminal deoxynucleotidyl transferase 
biotin-dUTP nick end labeling (TUNEL) staining using an 
in situ ApopTag kit for apoptosis detection, and anti-mouse 
CD31 immunostaining for tumor blood vessels, as we described 
previously [33]. All animal experiments were done according to 
the protocol approved by the University of Michigan Guidelines 
for Use and Care of Animals.
ALDEFLUOr assay
The ALDEFLUOR kit (Stem Cell Technologies) was 
applied to analyze the population with ALDH enzymatic 
activity using a FACS Calibur, as previously described [49]. 
Briefly, cells were incubated in ALDEFLUOR assay buffer 
containing ALDH substrate BAAA (1.5 µM per 1 × 106 
cells) at 37°C for 45 min. In each experiment, cells were also 
incubated under identical conditions with negative control, 
15 μM of ALDH inhibitor diethylaminobenzaldehyde. 
Cells with ALDH activity convert BAAA to the negatively 
charged fluorescent product, BAA, which can be measured 
fluorescence on a flow cytometer. To eliminate cells of 
mouse origin from the xeno-transplanted tumors, cells 
were firstly stained with an anti-H2Kd antibody (diluted 
1:200, 20 min on ice; BD Biosciences) followed by staining 
with a secondary antibody labeled with PE (diluted 1:250, 
20 min on ice; Jackson Labs) and then were subsequent to 
ALDEFLUOR assay.
stem cell Pcr array
Total RNAs isolated from PANC-1 cells treated 
with Lip-FLLL32 or Lip only were reverse transcribed 
into complementary DNA, and amplified by Human Stem 
Cell Primer Library (HSCL-I) from RealTime Primers 
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LLC (Elkins Park), which contains 88 primer sets directed 
against stem cell- related genes and 8 housekeeping gene 
primer sets as we described previously [17].
statistical analysis
Student t-test, one-way and two-way ANOVA were 
employed to analyze the in vitro and in vivo data using 
Prism 5.0 software (GraphPad). Categorical variables were 
compared using the x2 test. The Kaplan–Meier method and 
the log-rank test were used to compare overall survival, 
defined as the time of patients from surgery until death 
(patients alive were censored at the time of their last follow-
up), and were conducted with statistical analysis software 
program SPSS 13.0 software (IBM). *P < 0.05, **P < 0.01, 
***P < 0.001, as compared with the control group.
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